Harmen Beurmanjer

173 Supplements Population description and results Demographics: 95% male; 97% (GHB alone) and 94% (GHB combined with other drugs). Age: men M=26, SD=5.5, range 15-50 years; women M=32, SD=8, range 19-47 years; GHB alone: men M=25.3, SD=4.9 years; women M=34.0, SD=6.2 years; GHB combined: men M=26.4, SD=5.5 years; women M=31.3, SD=8.0 years. GHB use: M=89, median= 82, range=8-340 mg/L. GHB alone in 39%. GHB alone: M=91, median= 83, range 2.5-97.5 percentiles= 16-200 mg/L. GHB combined with other drugs: M=88, median= 81, range 2.5-97.5 percentiles= 10-227 mg/L. Mean concentration GHB tends to increase with age of offenders (P<0.05). Concentrations of GHB in blood and ages of offenders remained constant over the 10-year study period. Population description and results Demographics: Total population: 89% male; 26-39 (57%), 40-55 (39%) years old. GHB population (n=52): 92% male; 26-39 (77%), >40 (23%) years old; M=15.8 years of education. Non-GHB using population (n=48): 85% male; 18-25 (6%), 26-39 (38%), >40 (56%) years old; M=15.7 years of education. Other: Total population: gay (56%), heterosexual (33%). GHB population: gay (77%), heterosexual (13%). Non-GHB using population: gay (33%), heterosexual (54%). Eleven participants did not report sexual orientation. GHB use: 52% (ever), 43% (past 6 months); 37 respondents used 1-10 times and 3 respondents 16-20 times last 6 months. Most common effect was increased energy (21%), euphoria (18%), and weight lost (11%). Of the total responders, 24% knew about the addictive potential (27% among users). One participant reported severe adverse side effects. Population description and results Other substance use: GHB use more than 6 months ago: amyl nitrite (60.5%), cannabis (51.2%), ecstasy (39.5%), meth/ amphetamine (9.9%), cocaine (31.8%), crystal methamphetamine (28.2%), ketamine (7.7%), LSD (6.6%), heroin (0.3%). GHB use less than monthly pas6t 6 months: amyl nitrite (76.7%), cannabis (55.8%), ecstasy (66.3%), meth/ amphetamine (19.2%), cocaine (46.5%), crystal methamphetamine (70.3%), ketamine (21.5%), LSD (9.3%), heroin (1.2%). GHB monthly or more past 6 months: amyl nitrite (87.4%), cannabis (50.6%), ecstasy (64.4%), meth/ amphet- amine (21.8%), cocaine (56.3%), crystal methamphetamine (87.4%), ketamine (42.5%), LSD (10.3%), heroin (2.3%). Other: GHB use more than 6 months ago: depression: minimal (40.8%), mild (25.5%), moderate (12.6%), moderately severe (6.6%), severe (6.0%), did not answer (8.5%). Anxiety: minimal (52.3%), mild (24.4%), moderate (8.8%), severe (6.0%), did not answer (8.5%). GHB use less than monthly pas6t 6 months: depression: minimal (45.3%), mild (30.2%), moderate (9.3%), moderately severe (6.4%), severe (2.9%), did not answer (5.8%). Anxiety: minimal (59.9%), mild (25.0%), moderate (5.8%), severe (2.9%), did not answer (6.4%). GHB monthly or more past 6 months: depression: minimal (35.6%), mild (25.3%), moderate (12.6%), moderately severe (5.7%), severe (5.7%), did not answer (14.9%). Anxiety: minimal (43.7%), mild (24.1%), moderate (13.8%), severe (5.7%), did not answer (12.6%).